Aktiia OPBM Single-center Prospective Observational Study Against Double Auscultation

NCT ID: NCT04027777

Last Updated: 2024-02-01

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 185 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-08-06
• Study Completion Date: 2024-12-31

Brief Summary

Single-centre prospective observational study to validate the performance of the Aktiia SA optical blood pressure monitoring (OBPM) device at the wrist against blood pressure measurements obtained by double auscultation at the upper arm during four weeks

Detailed Description

According to the World Health Organization, by 2025 hypertension will affect 1.5 billion adults worldwide. Half of the adult population is not diagnosed, and half of the treated population is not at the defined target of BP. Widespread use of out of office BP measurement is one of the proposed strategies to fight against hypertension worldwide.

The current Ambulatory Blood Pressure Monitoring or Home Blood Pressure Monitoring are performed with a cuff placed around the arm. This 110-year-old technology is not only uncomfortable for the patient but can also result in a number of overestimated readings due to the stress induced while inflating the cuff.

Aktiia S.A. has developed an intermittent automated non-invasive cuffless blood pressure monitor determining over a series of cardiac cycles the values of the systolic blood pressure, the diastolic blood pressure and the heart rate. This miniature device is comfortably positioned with a bracelet on a user's wrist. The optical sensors integrated within the device exploit the principle of reflection photoplethysmography (PPG) to capture the user's skin pulsatility (change of arterial diameter occurring at each heartbeat). Aktiia OBPM algorithms are further applied to the recorded PPG signal to determine user's blood pressure and heart rate.

Because the measurement relies on optical sensors, and not on pneumatic cuffs, Aktiia OBPM device provides an increased overall comfort to the patient throughout the monitoring, does not induce sleep arousal during the night measurements and decreases the false positive readings induced by the stress associated with the cuff inflation. Aktiia OBPM device is intended to be used in the long term, as compared to one-day or one-week use of Ambulatory Blood Pressure Monitors.

This study over several visits has been designed to assess both the accuracy and the stability of the Aktiia OBPM. The automaticity of the measurement when performed in different body positions and upon aerobic exercise was also evaluated.

By demonstrating both the accuracy and the stability of the measurements that can be performed in different body positions with a comfortable and miniature Aktiia OBPM device, Aktiia SA aims to make one step further in facilitating blood pressure measurement and monitoring in the out-of-clinic scenarios and integrating blood pressure monitoring into user's daily life. The diagnosis and treatment of hypertension in ambulatory settings is expected to largely benefit from these advancements

Conditions

Blood Pressure

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SCREENING
• Blinding Strategy: NONE

Study Groups

Aktiia.product-P0

Main study arm including 85 subjects

Group Type: EXPERIMENTAL

Aktiia.product-P0

Intervention Type: DEVICE

The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.

Aktiia.product-P0 Diabetics

Second study arm including 40 diabetic patients

Group Type: EXPERIMENTAL

Aktiia.product-P0

Intervention Type: DEVICE

The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.

Aktiia.product-P0 Aged

Thirs study arm including 40 patients aged 65+

Group Type: EXPERIMENTAL

Aktiia.product-P0

Intervention Type: DEVICE

The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.

Interventions

Aktiia.product-P0

The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Adult subjects (aged between 21 and 65 years old)
• Subjects fluent in written and spoken French
• Subjects agreeing to attend the totality of 4 visits
• Subjects that have signed the informed consent form

• Adult subjects (aged between 21 and 65 years old)
• Subjects fluent in written and spoken French
• Subjects agreeing to attend the totality of 4 visits
• Subjects that have signed the informed consent form

• Adult subjects (aged between 65 and 85 years old)
• Subjects fluent in written and spoken French
• Subjects agreeing to attend the totality of 4 visits
• Subjects that have signed the informed consent form

Exclusion Criteria

• Subjects with tachycardia (heart rate at rest > 120bpm)
• Subjects with atrial fibrillation
• Subjects with diabetes
• Subjects with renal dysfunctions (eGFR < 60mL/min/1.73 m2)
• Subjects with hyper-/hypothyroidism
• Subjects with pheochromocytoma
• Subjects with Raynaud's disease
• Subjects with trembling and shivering
• Subjects with interarm systolic difference > 15 mmHg
• Subjects with interarm diastolic difference > 10 mmHg
• Subjects with arm paralysis
• Women in known pregnancy
• Subjects with an arteriovenous fistula
• Subjects with arm amputations
• Subjects with the upper arm circumference > 64 cm
• Subjects with the wrist circumference > 22 cm (limitation due Aktiia.bracelet-P0 size)
• Subjects with the central phalanx of the middle finger circumference > 71 mm or < 43 mm
• Subjects with the exfoliative skin diseases (limitation due to participant discomfort)
• Subjects with lymphoedema (limitation due to participant discomfort)

ARM2

• Subjects with tachycardia (heart rate at rest > 120bpm)
• Subjects with atrial fibrillation
• Subjects with hyper-/hypothyroidism
• Subjects with pheochromocytoma
• Subjects with Raynaud's disease
• Subjects with trembling and shivering
• Subjects with interarm systolic difference > 15 mmHg
• Subjects with interarm diastolic difference > 10 mmHg
• Subjects with arm paralysis
• Women in known pregnancy
• Subjects with an arteriovenous fistula
• Subjects with arm amputations
• Subjects with the upper arm circumference > 64 cm
• Subjects with the wrist circumference > 22 cm (limitation due Aktiia.bracelet-P0 size)
• Subjects with the central phalanx of the middle finger circumference > 71 mm or < 43 mm
• Subjects with the exfoliative skin diseases (limitation due to participant discomfort)
• Subjects with lymphoedema (limitation due to participant discomfort)

ARM3

• Subjects with tachycardia (heart rate at rest > 120bpm)
• Subjects with atrial fibrillation
• Subjects with diabetes
• Subjects with renal dysfunctions (eGFR < 60mL/min/1.73 m2)
• Subjects with hyper-/hypothyroidism
• Subjects with pheochromocytoma
• Subjects with Raynaud's disease
• Subjects with trembling and shivering
• Subjects with interarm systolic difference > 15 mmHg
• Subjects with interarm diastolic difference > 10 mmHg
• Subjects with arm paralysis
• Women in known pregnancy
• Subjects with an arteriovenous fistula
• Subjects with arm amputations
• Subjects with the upper arm circumference > 64 cm
• Subjects with the wrist circumference > 22 cm (limitation due Aktiia.bracelet-P0 size)
• Subjects with the central phalanx of the middle finger circumference > 71 mm or < 43 mm
• Subjects with the exfoliative skin diseases (limitation due to participant discomfort)
• Subjects with lymphoedema (limitation due to participant discomfort)

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Lausanne Hospitals

OTHER

Sponsor Role: collaborator

Aktiia SA

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Gregoire Wuerzner, MD

Role: PRINCIPAL_INVESTIGATOR

CHUV

Locations

University of Lausanne Hospitals

Lausanne, , Switzerland

Site Status: RECRUITING

Countries

Switzerland

Central Contacts

Josep Sola, PhD

Role: CONTACT

josep@aktiia.com

+41797689800

Facility Contacts

Grégoire Wuerzner, MD

Role: primary

gregoire.wuerzner@chuv.ch

+41213141131

References

Theiler K, Sola J, Damianaki A, Pfister A, Almeida TP, Alexandre J, Vermare P, Wuerzner G. Performance of the Aktiia optical blood pressure measurement device in the elderly: a comparison with double blinded auscultation in different body positions. Blood Press. 2023 Dec;32(1):2281320. doi: 10.1080/08037051.2023.2281320. Epub 2023 Nov 16.

Reference Type: DERIVED

PMID: 37971487 (View on PubMed)

Related Links

http://www.aktiia.com

Sponsor website

Other Identifiers

OBPM_Ambulatory2019

Identifier Type: -

Identifier Source: org_study_id